AN2 Looks To Shift Gears On Phase III Epetraborole Trial On Potentially Lackluster Results
The company said it was pausing enrollment in the Phase III segment of its Phase II/III trial because of efficacy in MAC lung disease.
You may also be interested in...
Insmed’s ARISE trial validated a patient-reported outcome measure it plans to use as the new primary endpoint in the ongoing pivotal ENCORE study, but it will ask the US FDA about accelerated approval based on ARISE.
Results from a Phase II trial have demonstrated the potential of GSK's first-in-class antitubercular agent to be a component of simpler treatment regimens for tuberculosis in the future.
Because it will be initially targeting specialists and a very sick population, the biotech thinks Arikayce will get early usage in its narrowly defined lung infection indication.